Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IlluminaSTU:ILU -0.07%75 EV-to-FCF is 33.45 as of Aug. 01, 2026, which is 38% below its 10-year median of 53.56. GuruFocus rates STU:ILU with a GF Score™ of 75/100 and a GF Value™ of €114.00 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 100 Medical Diagnostics & Research companies, Illumina ranks worse than 62% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Illumina's Enterprise Value is €28,110 Mil.
Illumina's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €840 Mil. Therefore, Illumina's EV-to-FCF for today is 33.45.
The historical rank and industry rank for Illumina's EV-to-FCF or its related term are showing as below:
STU:ILU'
s EV-to-FCF Range Over the Past 10 Years
Min: -776.23 Med: 53.56 Max: 668.15
Current: 33.12
During the past 13 years, the highest EV-to-FCF of Illumina was 668.15. The lowest was -776.23. And the median was 53.56.
STU:ILU's EV-to-FCF is ranked worse than 62% of 100
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.53
vs STU:ILU: 33.12
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Illumina's share price for today is €177.64.
Illumina's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.605.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Illumina EV-to-FCF Related Terms
Illumina EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Illumina's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Illumina's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Illumina's EV-to-FCF falls into.
Illumina's current Enterprise Value is €28,110 Mil.
Illumina's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €840 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (STU:ILU) has a EV-to-FCF of 33.45 as of Aug. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Illumina and its competitors. This is 38% below median its historical median of 53.56. According to the industry distribution chart, Illumina ranks #62 out of 100 companies in the Medical Diagnostics & Research industry, placing it in the top 62%.
Is Illumina's EV-to-FCF too high?
Illumina's current EV-to-FCF of 33.45 is 38% below median its 10-year median of 53.56. The Medical Diagnostics & Research industry median EV-to-FCF is 26.53. Illumina's value of 33.45 is 26.1% above this industry median. Based on the distribution chart, Illumina ranks #62 out of 100 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Illumina has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Illumina's EV-to-FCF compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #62 out of 100 companies for EV-to-FCF. This places Illumina in the lower half of its industry. The industry median EV-to-FCF is 26.53. Illumina's value of 33.45 is 26.1% above this benchmark. While the company's 10-year median is 53.56 vs. the industry median of 26.53, Illumina has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.53, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Illumina's current EV-to-FCF of 33.45 is 26.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Illumina and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current EV-to-FCF is 33.45, which is 38% below median its own 10-year median of 53.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Based on GuruFocus' analysis, Illumina (STU:ILU) is currently considered Significantly Overvalued. The stock's GF Value™ is €114.00, compared to a current price of €177.64 — trading 55.8% above its estimated fair value. The current EV-to-FCF is 33.45, which is 38% below median its 10-year median of 53.56 and 26.1% above the Medical Diagnostics & Research industry median of 26.53. Illumina's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Illumina (STU:ILU), the current EV-to-FCF is 33.45 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (STU:ILU) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of €177.64 is trading 55.8% above its estimated GF Value™ of €114.00.
GuruFocus considers Illumina to be Significantly Overvalued.
Key valuation signals for STU:ILU:
EV-to-FCF: 33.45 (38% below median its 10-year median of 53.56)
GF Value™: €114.00 vs. price of €177.64 (55.8% above fair value)
Industry Position: 26.1% above the Medical Diagnostics & Research median (#62 of 100)
No single metric tells the full story. See the STU:ILU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
75GF Score
Get the complete analysis for STU:ILU
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ILU has been successfully added to your 
